AbbVie Inc. (XETRA: 4AB.DE) Stock Competitors & Peer Comparison
See 4AB.DE's competitors and their performance on the XETRA and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for 4AB.DE and its XETRA peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| 4AB.DE | €228.40 | +1.02% | 403.5B | 39.99 | €5.71 | +2.58% |
| LLY.DE | €1,080.40 | +1.60% | 1T | 40.83 | €26.46 | +0.54% |
| JNJ.DE | €234.20 | +1.08% | 564.4B | 26.29 | €8.91 | +1.94% |
| NOVC.DE | €91.40 | -1.98% | 406.7B | 22.91 | €3.99 | +12.20% |
| 4AB.DU | €227.40 | +0.22% | 401.8B | 39.82 | €5.71 | +2.57% |
| 6MK.DE | €132.16 | +2.23% | 326.4B | 52.90 | €2.50 | +2.22% |
| ZEG.DE | €160.70 | +0.59% | 249.2B | 26.61 | €6.04 | +1.12% |
| AMG.DE | €382.20 | +1.08% | 206.3B | 19.82 | €19.28 | +2.25% |
| NOV.DE | €41.56 | +3.09% | 184.6B | 13.32 | €3.12 | +2.50% |
| GIS.DE | €126.78 | +1.52% | 157.4B | -102.21 | -€1.24 | +2.21% |
Stock Comparison
Eli Lilly and Company (XETRA: LLY.DE)
4AB.DE vs LLY.DE Comparison August 2026
AbbVie Inc. (XETRA: 4AB.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4AB.DE stands at 403.5B. In comparison, LLY.DE has a market cap of 1T. Regarding current trading prices, 4AB.DE is priced at €228.40 on the XETRA, while LLY.DE trades at €1,080.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4AB.DE currently has a P/E ratio of 39.99, whereas LLY.DE's P/E ratio is 40.83. In terms of profitability, 4AB.DE's ROE is -1.37%, compared to LLY.DE's ROE of +0.93%. Regarding short-term risk, 4AB.DE is less volatile compared to LLY.DE. This indicates lower risk in terms of short-term price fluctuations for 4AB.DE.Check LLY.DE's competition here
Johnson & Johnson (XETRA: JNJ.DE)
4AB.DE vs JNJ.DE Comparison August 2026
AbbVie Inc. (XETRA: 4AB.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4AB.DE stands at 403.5B. In comparison, JNJ.DE has a market cap of 564.4B. Regarding current trading prices, 4AB.DE is priced at €228.40 on the XETRA, while JNJ.DE trades at €234.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4AB.DE currently has a P/E ratio of 39.99, whereas JNJ.DE's P/E ratio is 26.29. In terms of profitability, 4AB.DE's ROE is -1.37%, compared to JNJ.DE's ROE of +0.26%. Regarding short-term risk, 4AB.DE is less volatile compared to JNJ.DE. This indicates lower risk in terms of short-term price fluctuations for 4AB.DE.Check JNJ.DE's competition here
Novo Nordisk A/S (XETRA: NOVC.DE)
4AB.DE vs NOVC.DE Comparison August 2026
AbbVie Inc. (XETRA: 4AB.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4AB.DE stands at 403.5B. In comparison, NOVC.DE has a market cap of 406.7B. Regarding current trading prices, 4AB.DE is priced at €228.40 on the XETRA, while NOVC.DE trades at €91.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4AB.DE currently has a P/E ratio of 39.99, whereas NOVC.DE's P/E ratio is 22.91. In terms of profitability, 4AB.DE's ROE is -1.37%, compared to NOVC.DE's ROE of +0.88%. Regarding short-term risk, 4AB.DE is less volatile compared to NOVC.DE. This indicates lower risk in terms of short-term price fluctuations for 4AB.DE.Check NOVC.DE's competition here
AbbVie Inc. (DUS: 4AB.DU)
4AB.DE vs 4AB.DU Comparison August 2026
AbbVie Inc. (XETRA: 4AB.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4AB.DE stands at 403.5B. In comparison, 4AB.DU has a market cap of 401.8B. Regarding current trading prices, 4AB.DE is priced at €228.40 on the XETRA, while 4AB.DU trades at €227.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4AB.DE currently has a P/E ratio of 39.99, whereas 4AB.DU's P/E ratio is 39.82. In terms of profitability, 4AB.DE's ROE is -1.37%, compared to 4AB.DU's ROE of -1.37%. Regarding short-term risk, 4AB.DE is more volatile compared to 4AB.DU. This indicates higher risk in terms of short-term price fluctuations for 4AB.DE.Check 4AB.DU's competition here
Merck & Co., Inc. (XETRA: 6MK.DE)
4AB.DE vs 6MK.DE Comparison August 2026
AbbVie Inc. (XETRA: 4AB.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4AB.DE stands at 403.5B. In comparison, 6MK.DE has a market cap of 326.4B. Regarding current trading prices, 4AB.DE is priced at €228.40 on the XETRA, while 6MK.DE trades at €132.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4AB.DE currently has a P/E ratio of 39.99, whereas 6MK.DE's P/E ratio is 52.90. In terms of profitability, 4AB.DE's ROE is -1.37%, compared to 6MK.DE's ROE of +0.07%. Regarding short-term risk, 4AB.DE is less volatile compared to 6MK.DE. This indicates lower risk in terms of short-term price fluctuations for 4AB.DE.Check 6MK.DE's competition here
AstraZeneca PLC (XETRA: ZEG.DE)
4AB.DE vs ZEG.DE Comparison August 2026
AbbVie Inc. (XETRA: 4AB.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4AB.DE stands at 403.5B. In comparison, ZEG.DE has a market cap of 249.2B. Regarding current trading prices, 4AB.DE is priced at €228.40 on the XETRA, while ZEG.DE trades at €160.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4AB.DE currently has a P/E ratio of 39.99, whereas ZEG.DE's P/E ratio is 26.61. In terms of profitability, 4AB.DE's ROE is -1.37%, compared to ZEG.DE's ROE of +0.22%. Regarding short-term risk, 4AB.DE is less volatile compared to ZEG.DE. This indicates lower risk in terms of short-term price fluctuations for 4AB.DE.Check ZEG.DE's competition here
Amgen Inc. (XETRA: AMG.DE)
4AB.DE vs AMG.DE Comparison August 2026
AbbVie Inc. (XETRA: 4AB.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4AB.DE stands at 403.5B. In comparison, AMG.DE has a market cap of 206.3B. Regarding current trading prices, 4AB.DE is priced at €228.40 on the XETRA, while AMG.DE trades at €382.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4AB.DE currently has a P/E ratio of 39.99, whereas AMG.DE's P/E ratio is 19.82. In terms of profitability, 4AB.DE's ROE is -1.37%, compared to AMG.DE's ROE of +0.89%. Regarding short-term risk, 4AB.DE is more volatile compared to AMG.DE. This indicates higher risk in terms of short-term price fluctuations for 4AB.DE.Check AMG.DE's competition here
Novo Nordisk A/S (XETRA: NOV.DE)
4AB.DE vs NOV.DE Comparison August 2026
AbbVie Inc. (XETRA: 4AB.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4AB.DE stands at 403.5B. In comparison, NOV.DE has a market cap of 184.6B. Regarding current trading prices, 4AB.DE is priced at €228.40 on the XETRA, while NOV.DE trades at €41.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4AB.DE currently has a P/E ratio of 39.99, whereas NOV.DE's P/E ratio is 13.32. In terms of profitability, 4AB.DE's ROE is -1.37%, compared to NOV.DE's ROE of +0.59%. Regarding short-term risk, 4AB.DE is less volatile compared to NOV.DE. This indicates lower risk in terms of short-term price fluctuations for 4AB.DE.Check NOV.DE's competition here
Gilead Sciences, Inc. (XETRA: GIS.DE)
4AB.DE vs GIS.DE Comparison August 2026
AbbVie Inc. (XETRA: 4AB.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4AB.DE stands at 403.5B. In comparison, GIS.DE has a market cap of 157.4B. Regarding current trading prices, 4AB.DE is priced at €228.40 on the XETRA, while GIS.DE trades at €126.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4AB.DE currently has a P/E ratio of 39.99, whereas GIS.DE's P/E ratio is -102.21. In terms of profitability, 4AB.DE's ROE is -1.37%, compared to GIS.DE's ROE of -0.16%. Regarding short-term risk, 4AB.DE is less volatile compared to GIS.DE. This indicates lower risk in terms of short-term price fluctuations for 4AB.DE.Check GIS.DE's competition here
Pfizer Inc. (XETRA: PFE.DE)
4AB.DE vs PFE.DE Comparison August 2026
AbbVie Inc. (XETRA: 4AB.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4AB.DE stands at 403.5B. In comparison, PFE.DE has a market cap of 139.3B. Regarding current trading prices, 4AB.DE is priced at €228.40 on the XETRA, while PFE.DE trades at €24.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4AB.DE currently has a P/E ratio of 39.99, whereas PFE.DE's P/E ratio is 10.55. In terms of profitability, 4AB.DE's ROE is -1.37%, compared to PFE.DE's ROE of +0.05%. Regarding short-term risk, 4AB.DE is less volatile compared to PFE.DE. This indicates lower risk in terms of short-term price fluctuations for 4AB.DE.Check PFE.DE's competition here
Bristol-Myers Squibb Company (XETRA: BRM.DE)
4AB.DE vs BRM.DE Comparison August 2026
AbbVie Inc. (XETRA: 4AB.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4AB.DE stands at 403.5B. In comparison, BRM.DE has a market cap of 118.5B. Regarding current trading prices, 4AB.DE is priced at €228.40 on the XETRA, while BRM.DE trades at €58.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4AB.DE currently has a P/E ratio of 39.99, whereas BRM.DE's P/E ratio is 14.85. In terms of profitability, 4AB.DE's ROE is -1.37%, compared to BRM.DE's ROE of +0.47%. Regarding short-term risk, 4AB.DE is less volatile compared to BRM.DE. This indicates lower risk in terms of short-term price fluctuations for 4AB.DE.Check BRM.DE's competition here
Sanofi (XETRA: SNW.DE)
4AB.DE vs SNW.DE Comparison August 2026
AbbVie Inc. (XETRA: 4AB.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4AB.DE stands at 403.5B. In comparison, SNW.DE has a market cap of 94.5B. Regarding current trading prices, 4AB.DE is priced at €228.40 on the XETRA, while SNW.DE trades at €78.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4AB.DE currently has a P/E ratio of 39.99, whereas SNW.DE's P/E ratio is 24.31. In terms of profitability, 4AB.DE's ROE is -1.37%, compared to SNW.DE's ROE of +0.09%. Regarding short-term risk, 4AB.DE is more volatile compared to SNW.DE. This indicates higher risk in terms of short-term price fluctuations for 4AB.DE.Check SNW.DE's competition here
Bayer Aktiengesellschaft (XETRA: BAYN.DE)
4AB.DE vs BAYN.DE Comparison August 2026
AbbVie Inc. (XETRA: 4AB.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4AB.DE stands at 403.5B. In comparison, BAYN.DE has a market cap of 48.4B. Regarding current trading prices, 4AB.DE is priced at €228.40 on the XETRA, while BAYN.DE trades at €49.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4AB.DE currently has a P/E ratio of 39.99, whereas BAYN.DE's P/E ratio is 10.19. In terms of profitability, 4AB.DE's ROE is -1.37%, compared to BAYN.DE's ROE of -0.06%. Regarding short-term risk, 4AB.DE is less volatile compared to BAYN.DE. This indicates lower risk in terms of short-term price fluctuations for 4AB.DE.Check BAYN.DE's competition here
Bayer Aktiengesellschaft (STU: BAYN.SG)
4AB.DE vs BAYN.SG Comparison August 2026
AbbVie Inc. (XETRA: 4AB.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4AB.DE stands at 403.5B. In comparison, BAYN.SG has a market cap of 48.3B. Regarding current trading prices, 4AB.DE is priced at €228.40 on the XETRA, while BAYN.SG trades at €49.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4AB.DE currently has a P/E ratio of 39.99, whereas BAYN.SG's P/E ratio is -43.08. In terms of profitability, 4AB.DE's ROE is -1.37%, compared to BAYN.SG's ROE of -0.06%. Regarding short-term risk, 4AB.DE is less volatile compared to BAYN.SG. This indicates lower risk in terms of short-term price fluctuations for 4AB.DE.Check BAYN.SG's competition here
Biogen Inc. (XETRA: IDP.DE)
4AB.DE vs IDP.DE Comparison August 2026
AbbVie Inc. (XETRA: 4AB.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4AB.DE stands at 403.5B. In comparison, IDP.DE has a market cap of 24.5B. Regarding current trading prices, 4AB.DE is priced at €228.40 on the XETRA, while IDP.DE trades at €165.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4AB.DE currently has a P/E ratio of 39.99, whereas IDP.DE's P/E ratio is 14.83. In terms of profitability, 4AB.DE's ROE is -1.37%, compared to IDP.DE's ROE of +0.05%. Regarding short-term risk, 4AB.DE is less volatile compared to IDP.DE. This indicates lower risk in terms of short-term price fluctuations for 4AB.DE.Check IDP.DE's competition here
GSK plc (XETRA: GS7.DE)
4AB.DE vs GS7.DE Comparison August 2026
AbbVie Inc. (XETRA: 4AB.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 4AB.DE stands at 403.5B. In comparison, GS7.DE has a market cap of 0. Regarding current trading prices, 4AB.DE is priced at €228.40 on the XETRA, while GS7.DE trades at €20.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
4AB.DE currently has a P/E ratio of 39.99, whereas GS7.DE's P/E ratio is 17.31. In terms of profitability, 4AB.DE's ROE is -1.37%, compared to GS7.DE's ROE of +0.26%. Regarding short-term risk, 4AB.DE is less volatile compared to GS7.DE. This indicates lower risk in terms of short-term price fluctuations for 4AB.DE.Check GS7.DE's competition here